AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsInformation ScienceHealth Care
Carcinoma, NeuroendocrineNeuroendocrine TumorsCarcinoma, Large CellCarcinoid TumorCarcinomaNeurosecretory SystemsCarcinoma, Merkel CellCarcinoma, Small CellNeoplasms, Complex and MixedChromograninsCarcinoma, Squamous CellNeuroendocrine CellsImmunohistochemistryNeoplasms, MesothelialSynaptophysinLung NeoplasmsChromogranin ATumor Markers, BiologicalCommon Bile Duct NeoplasmsFatal OutcomeCarcinoma, HepatocellularAmpulla of VaterPancreatic NeoplasmsGastrointestinal NeoplasmsThymus NeoplasmsLiver NeoplasmsParanasal Sinus NeoplasmsLaryngeal NeoplasmsBronchial NeoplasmsNeoplasms, Multiple PrimaryAdenocarcinomaPrognosisOctreotideGallbladder NeoplasmsCarcinoma, MedullaryCarcinoma in SituTomography, X-Ray ComputedNeoplasm StagingIleal NeoplasmsAnal SacsTreatment OutcomeEnterochromaffin CellsCarcinoma, PapillaryBiliary Tract NeoplasmsRetrospective StudiesEtoposideTissue Array AnalysisLymphatic MetastasisNose NeoplasmsImmunoenzyme TechniquesNeoplasm InvasivenessStomach NeoplasmsNeoplasm MetastasisBiopsyAntineoplastic AgentsCarcinoma, Ductal, BreastCombined Modality TherapySkin NeoplasmsCarcinoma, Basal CellCisplatinKeratinsMediastinal NeoplasmsBreast NeoplasmsCell Line, TumorCalcitoninCat DiseasesHead and Neck NeoplasmsNeuroendocrine Secretory Protein 7B2Survival AnalysisAntineoplastic Combined Chemotherapy ProtocolsPancreaticoduodenectomySurvival RateKaplan-Meier EstimateUterine Cervical NeoplasmsGenes, p16Loss of HeterozygosityTherapeutics
Tumors2023UrothelialImmunomic TherapeuticsMerkelTumoursRenalAcinarMutationsDifferentiationSquamousCellsMolecularDisease progressionCancer ResearchEpidermal growth fChemotherapyProstateEverolimusAfinitorDiagnosisPrognosisColorectal cancerInhibitorsMTORStudySkin cancerProliferationVariationsFeaturesDevelopmentLossLargeProtein
Tumors9
  • Blocking mTOR's action may keep cancer cells from growing and prevent the growth of new blood vessels that tumors need to grow. (ronnyallan.net)
  • Sanction allows use of the drug to treat patients with pancreatic neuroendocrine tumors. (genengnews.com)
  • Pfizer's Sutent gained approval from the European Commission for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors with disease progression in adults. (genengnews.com)
  • Two important Sutent targets, vascular endothelial growth factor receptor and platelet-derived growth factor receptor, are expressed by many types of solid tumors and are thought to play a crucial role in angiogenesis. (genengnews.com)
  • Today's sanction in pancreatic neuroendocrine tumors is based on results from a randomized, Phase III trial conducted in 171 patients. (genengnews.com)
  • On December 16, 2022, the Food and Drug Administration approved nadofaragene firadenovec-vncg (Adstiladrin, Ferring Pharmaceuticals) for adult patients with high-risk Bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. (privacytools.io)
  • Conclusions: We observed novel mutations in primary/metastatic carcinoid tumor pairs, and some have been observed in other types of neuroendocrine tumors. (bvsalud.org)
  • Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) account for 80% of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). (bvsalud.org)
  • Paralleling the emergence of targeted therapeutics in cancer treatment, a variety of experimental approaches has led to the conclusion that tumors bearing some specific genetic alterations may lead them to be uniquely sensitive to agents deregulating their cellular metabolism. (aacrjournals.org)
20231
  • It is also expected that the global breast cancer therapeutics market will exhibit an 8.4% CAGR from 2015 to 2023, rising to a revenue opportunity of US$16.21 bn by 2023. (wikikenko.com)
Urothelial2
  • Correlation between PD-L1 expression of the tumour cells and lymphocytes infiltration in the invasive front of urothelial carcinoma Chen X, Chen H, Lin R, Li Y, Guo Y, Chen Q, Zhang Y, Cai G , Hu M, Chen G. Correlation between PD-L1 expression of the tumour cells and lymphocytes infiltration in the invasive front of urothelial carcinoma. (yale.edu)
  • This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with ultralow dose gemcitabine in participants with platinum-resistant ovarian carcinoma , endometrial adenocarcinoma , and urothelial carcinoma based on Acrivon's OncoSignature® test status. (ucsd.edu)
Immunomic Therapeutics1
  • ROCKVILLE, Md.--( BUSINESS WIRE )-- Immunomic Therapeutics Inc., ("ITI"), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy, announced today that the data from two posters are being presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 held in New Orleans, Louisiana, from April 8-13. (biospace.com)
Merkel14
  • These posters to be presented at the AACR Meeting focus on the investigational nucleic acid platform, UNITE™ (UNiversal Intracellular Targeted Expression) for two vaccines, ITI-3000 for Merkel cell carcinoma (targeting the large T antigen of the Merkel cell polyomavirus) and Her2/Neu-LAMP DNA vaccine, both of which fuse a tumor associated antigen with lysosomal associated membrane protein 1 (LAMP-1). (biospace.com)
  • This presentation reports results of pre-clinical mouse studies of a cancer vaccine that promotes potent, antigen-specific CD4 T cell responses to MCPγV-LT. The majority of Merkel cell carcinomas (MCC), a rare and highly aggressive type of neuroendocrine skin cancer, are associated with Merkel cell polyomavirus (MCPyV) infection. (biospace.com)
  • The Merkel Cell Carcinoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. (usmarketnewslatest.com)
  • Furthermore, launching various multiple-stage Merkel Cell Carcinoma pipeline products will significantly revolutionize the Merkel Cell Carcinoma market dynamics. (usmarketnewslatest.com)
  • DelveInsight's "Merkel Cell Carcinoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Merkel Cell Carcinoma, historical and forecasted epidemiology as well as the Merkel Cell Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. (usmarketnewslatest.com)
  • The Merkel Cell Carcinoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. (usmarketnewslatest.com)
  • Merkel cell carcinoma (MCC) is a rare but highly aggressive skin cancer with neuroendocrine features. (usmarketnewslatest.com)
  • As per "Skin Cancer Foundation", Merkel cell carcinoma (MCC) is 40 times more rare than melanoma, with an estimated one case per 130,000 people in the US. (usmarketnewslatest.com)
  • Epidemiologic data suggest that there are approximately 2500 new Merkel cell carcinoma cases per year within the European Union (EU), and approximately 1000 of these patients will die from their disease. (usmarketnewslatest.com)
  • Merkel Cell Carcinoma market report covers a descriptive overview and comprehensive insight of the Merkel Cell Carcinoma Epidemiology and Merkel Cell Carcinoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan. (usmarketnewslatest.com)
  • The Merkel Cell Carcinoma market report provides insights on the current and emerging therapies. (usmarketnewslatest.com)
  • Merkel Cell Carcinoma market report provides a global historical and forecasted market covering drug outreach in 7MM. (usmarketnewslatest.com)
  • The Merkel Cell Carcinoma market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Merkel Cell Carcinoma market. (usmarketnewslatest.com)
  • The dynamics of the Merkel Cell Carcinoma market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. (usmarketnewslatest.com)
Tumours1
  • On 2 May, the US Food and Drug Administration (FDA) rejected HUTCHMED's new drug application (NDA) for its lead candidate, Sulanda (surufatinib), for the treatment of advanced neuroendocrine tumours (NETs). (ronnyallan.net)
Renal2
  • The drug is also approved for Renal Cell Carcinoma (RCC) and hormone-receptor-positive advanced Breast Cancer.The drug is administered in oral form (tablet). (ronnyallan.net)
  • Sutent, an oral multikinase inhibitor, was previously approved for the treatment of advanced/metastatic renal cell carcinoma and unresectable and/or metastatic malignant gastrointestinal stromal tumor after failure of imatinib mesilate treatment due to resistance or intolerance. (genengnews.com)
Acinar1
  • Cytomorphologic, immunophenotypical and molecular features of pancreatic acinar cell carcinoma Sun T, Gilani S, Jain D, Cai G. Cytomorphologic, immunophenotypical and molecular features of pancreatic acinar cell carcinoma. (yale.edu)
Mutations2
  • Activating mutations in downstream genes of the epidermal growth factor receptor (EGFR) pathway may cause anti-EGFR resistance in patients with colorectal cancers. (ecologicalsgardens.com)
  • A concomitant mutation was detected in 51% of Mouse monoclonal to HER-2 23% of and 33% of kinase-impaired mutations but only mutations in neuroendocrine carcinomas. (ecologicalsgardens.com)
Differentiation2
  • It is unclear if the morphologic pattern and appearance of neuroendocrine differentiation varies based on the type of anti-androgen regimen. (healthyprostateclub.com)
  • More importantly, given the rise and progress in molecular pathology particularly in fields such as pulmonary adenocarcinomas, it is of great current interest to know any molecular variations in post ADT neuroendocrine differentiation and pure NEPC. (healthyprostateclub.com)
Squamous1
Cells6
  • Drugs used in combination chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (stanford.edu)
  • Vaccination with LTS220A-UNITE (ITI-3000) induced antigen-specific CD4 Th1 cells that was associated with delayed tumor growth and enhanced survival in treated mice in both the prophylactic and therapeutic settings. (biospace.com)
  • Vascular endothelial growth factor receptor-2 (VEGFR2) is a member of the VEGF family of receptor tyrosine kinase proteins, which are expressed on both endothelial and tumor cells, are one of the key proteins contributing to cancer development, and are involved in drug resistance. (researchgate.net)
  • 1500 cells/µL without growth factor support within 1 week prior to obtaining the hematology values at Screening. (ucsd.edu)
  • Everolimus under the trade name of Afinitor is a cancer medicine that interferes with the growth of cancer cells and slows their spread in the body. (wikikenko.com)
  • Notch signaling cascades crosstalk with fibroblast growth factor and WNT signaling cascades in the tumor microenvironment to maintain cancer stem cells and remodel the tumor microenvironment. (spandidos-publications.com)
Molecular2
  • Here we discuss the molecular mechanisms through which alimentary cues modulate metabolic, microbial and neuroendocrine circuitries and thus affect the probability of developing premalignant lesions that progress to clinically manifested disease and the response to therapeutic intervention. (nature.com)
  • It works by blocking multiple molecular targets implicated in the growth, proliferation, and spread of cancer, according to Pfizer. (genengnews.com)
Disease progression1
  • Biochemical recurrence (eg, CA-125 in ovarian carcinoma ) only is not considered as disease progression. (ucsd.edu)
Cancer Research1
  • The emergence of these findings, suggesting a direct control of cellular metabolism by tumorigenic pathways, has helped fuel explosive growth in this area of cancer research. (aacrjournals.org)
Epidermal growth f1
  • We have reported that trastuzumab, a humanized anti-human epidermal growth factor receptor 2 antibody, could exert remarkable antitumor effects against SCLC mainly through antibody-dependent cell-mediated cytotoxicity (ADCC) in preclinical models and clinical settings. (esmed.org)
Chemotherapy3
  • Tumor growth is initially reduced by radiation, surgery, or hormone therapy and later, by pairing them with chemotherapy for advanced cancer. (mdpi.com)
  • Signatures of prior exposures to DNA damaging agents - including chemotherapy - tend to associate with drug resistance, while signatures of deficiencies in DNA repair tend to predict sensitivity towards particular therapeutics. (nature.com)
  • SCLC is characterized by its rapid growth, early dissemination, and easy acquisition of multidrug resistance to chemotherapy. (esmed.org)
Prostate1
  • 2004). FAK is necessary for mammary tumor development also, intestinal tumorigenesis, as well as the androgen-independent development of neuroendocrine carcinoma inside a mouse style of prostate tumor (Ashton et?al. (ufe-eg.org)
Everolimus1
  • Click picture to read the A to Z of Neuroendocrine Cancer What is Everolimus (Afinitor)? (ronnyallan.net)
Afinitor1
  • AFINITOR reduces cell growth, proliferation, and angiogenesis. (wikikenko.com)
Diagnosis2
  • Diagnosis of acinic cell carcinoma of the salivary gland on cytology specimens: Role of NOR‐1 (NR4A3) immunohistochemistry Meiklejohn K, Hrones M, Wang M, Prasad M, Cai G , Adeniran A, Gilani S. Diagnosis of acinic cell carcinoma of the salivary gland on cytology specimens: Role of NOR‐1 (NR4A3) immunohistochemistry. (yale.edu)
  • This ENETS guidance paper, developed by a multidisciplinary working group, provides up-to-date and practical advice on the diagnosis and management of digestive neuroendocrine carcinoma, based on recent developments and study results. (ronnyallan.net)
Prognosis1
  • Clinical features and prognosis of advanced intra- and extra-pulmonary neuroendocrine carcinomas. (edu.ni)
Colorectal cancer1
  • Cetuximab and ramucirumab may also stop the growth of colorectal cancer by blocking blood flow to the tumor. (stanford.edu)
Inhibitors1
  • 2005), and FAK inhibitors Escitalopram oxalate are becoming created as potential tumor therapeutics (Roberts et?al. (ufe-eg.org)
MTOR1
  • The TSC1/TSC2 complex helps control the process of cell growth and proliferation by inhibiting mTOR. (wikikenko.com)
Study1
  • Behavioral endocrinology is the study of hormonal processes and neuroendocrine systems that influence or regulate behavior. (conferenceseries.com)
Skin cancer1
  • Basal cell carcinoma (BCC) is the most common nonmelanoma skin cancer (NMSC) worldwide, in particular, in fair-skinned population and its incidence has been rising over the past several years [ 1 - 3 ]. (hindawi.com)
Proliferation1
  • This hyperactivation leads to dysregulated cell growth and uncontrolled cell proliferation and hamartoma formation throughout the body. (wikikenko.com)
Variations1
  • Pediatric endocrinology is a medical subspecialty dealing with variations of physical growth and sexual development in childhood, as well as diabetes and other disorders of the endocrine glands . (conferenceseries.com)
Features1
  • GATA3 expression in primary lung carcinomas: correlation with histopathologic features and TTF-1, napsin A, and p40 expression Wang M, Chen P, Cai G . GATA3 expression in primary lung carcinomas: correlation with histopathologic features and TTF-1, napsin A, and p40 expression. (yale.edu)
Development1
  • These data suggest that Rb loss is a critical event in the development of small cell carcinomas and may be a useful diagnostic and potential therapeutic target. (healthyprostateclub.com)
Loss1
Large1
Protein1
  • The only ligand recognized to bind MST1R (RON) is Macrophage Stimulating 1 (MST1), also known as Macrophage Stimulating Protein (MSP) or Hepatocyte Growth Factor-Like Protein (HGFL). (frontiersin.org)